Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD38 as a prognostic marker in CLL.

Zoltan Matrai1

  • 1Department of Clinical Haematology, national Medical Center, Budapest, Hungary. matraiz@hotmail.com

Hematology (Amsterdam, Netherlands)
|July 16, 2005
PubMed
Summary

CD38 cell-surface expression in Chronic Lymphocytic Leukemia (CLL) indicates progressive disease and poor prognosis. Measuring CD38 aids in early identification of patients who may benefit from intensive therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Note: B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ Between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia.

Cancer research·2026
Same author

Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Neutrophil-to-Lymphocyte Ratio May be the Best Serological Biomarker in Predicting Longer Survival in Neoadjuvant Treatment of Triple-Negative Breast Cancer.

Cancer investigation·2025
Same author

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • CD38 expression on B-cells is a recognized prognostic marker in Chronic Lymphocytic Leukemia (CLL).
  • CD38 identifies progressive disease and poor outcomes, offering advantages over traditional staging systems.
  • Early identification of high-risk CLL patients is crucial for timely and intensive treatment strategies.

Purpose of the Study:

  • To evaluate the prognostic significance of CD38 expression in CLL.
  • To explore the utility of CD38 as an early diagnostic and prognostic tool in CLL.
  • To assess the correlation of CD38 expression with other prognostic factors like p53 and ZAP-70.

Main Methods:

  • Flow cytometry analysis of cell-surface CD38 expression in CLL patients.
  • Correlation of CD38 expression levels with clinical outcomes and disease progression.
  • Comparison of CD38 as a prognostic marker with established factors such as p53 and ZAP-70.

Main Results:

  • CD38 expression serves as a marker for progressive CLL and predicts poor prognosis.
  • CD38 positivity is associated with unmutated IgVH gene status in a majority of cases.
  • CD38 facilitates early identification of patients who may benefit from intensified therapeutic approaches.

Conclusions:

  • CD38 is a valuable tool for routine CLL diagnostics due to its prognostic significance and ease of application.
  • Further research is needed to clarify CD38 variations during disease course, optimal detection methods, and methodological impacts.
  • Defining CD38's definitive role in CLL diagnostics requires resolution of remaining questions regarding its variability and measurement.

Related Experiment Videos